Join
Live feed
·
PRReleasevia Quantisnow
Akari Therapeutics plc logo

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

ByQuantisnow·Wall Street's wire, on your screen.
AKTX· Akari Therapeutics plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AKTX (Akari Therapeutics plc) and more on Quantisnow.